Pulmonary Embolism
539
55
75
303
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
68 trials with published results (13%)
Research Maturity
303 completed trials (56% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.1%
38 terminated out of 539 trials
88.9%
+2.3% vs benchmark
18%
98 trials in Phase 3/4
22%
68 of 303 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 303 completed trials
Clinical Trials (539)
Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms
Aspiration Thrombectomy Using the Symphony or Prodigy System
Nurses' Health Study (Cardiovascular Component)
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
Diagnostic Strategy for Suspected Pulmonary Embolism Based on 4PEPS
Current Status and Determinants of Care for Patients With Acute Chest Pain in China: A Retrospective Analysis of Data From the China Chest Pain Center Registry
The PEERLESS II Study
The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
Timing of Thromboprophylaxis After Postpartum Hemorrhage
The PERSEVERE Study
Inari VISION Registry
Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism
Contribution of Lower Limb Venous Colour Doppler Ultrasound in the Diagnosis of Pulmonary Embolism Recurrence
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
Percutaneous Embolectomy, Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY II)
Pulmonary Embolism International THrOmbolysis Study-3
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism